Paper Details

  1. Home
  2. Paper Details

Exploring the potential of approved drugs for triple-negative breast cancer treatment by targeting casein kinase 2: Insights from computational studies.

Author: ALsiyudDuaa Fahad, AbdelrahmanMohammed, AlmadaniSara A, AlzainAbdulrahim A, AshourAhmed, GhazawiKholoud F, IbraheemWalaa, IbrahimSabrin R M, MiskiSamar F, MohamedGamal A, OsmanWadah, SherifAsmaa E, ShoaibTagyedeen H

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the potential of seven approved drugs as therapeutic agents against human ck2 alpha kinase, a key driver of triple-negative breast cancer (TNBC) metastasis and invasiveness. In silico analysis identified etravirine, an FDA-approved antiviral drug, as the most promising candidate. Molecular docking and simulations indicated a stable and reliable binding mode with the protein, suggesting potential antitumor activity. Further investigation into the use of etravirine, potentially through gold nanocarriers, is warranted.
Paper Details　
Original Abstract of the Article :
Triple-negative breast cancer (TNBC) is an aggressive malignancy that requires effective targeted drug therapy. In this study, we employed in silico methods to evaluate the efficacy of seven approved drugs against human ck2 alpha kinase, a significant modulator of TNBC metastasis and invasiveness. M...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424868/

データ提供：米国国立医学図書館（NLM）

Repurposing Approved Drugs for Triple-Negative Breast Cancer: Targeting Casein Kinase 2

The battle against triple-negative breast cancer (TNBC), a particularly aggressive form of breast cancer, demands innovative and effective therapies. This research explores the potential of repurposing existing drugs for TNBC treatment by targeting casein kinase 2 (CK2), a key protein implicated in TNBC progression. This research, like a desert traveler seeking a new route, explores the potential of repurposing existing drugs to fight TNBC, a challenging foe.

Repurposing Approved Drugs for Triple-Negative Breast Cancer: Identifying Potential Candidates

The study utilizes in silico methods, including molecular docking and molecular dynamics simulations, to identify potential drug candidates for targeting CK2. This research, like a skilled navigator charting a course across the desert, meticulously analyzes existing drugs to identify those with the potential to combat TNBC by inhibiting CK2.

Repurposing Approved Drugs for Triple-Negative Breast Cancer: Etravirine Shows Promise

The study identifies etravirine, an FDA-approved antiviral drug, as a promising candidate for repurposing as a TNBC treatment. This research, like a desert oasis revealing a hidden treasure, unveils the potential of etravirine to combat TNBC by targeting CK2. The study suggests that etravirine could provide a new avenue for treating TNBC, offering a glimmer of hope for patients facing this aggressive disease.

Dr.Camel's Conclusion

This study offers a promising avenue for repurposing existing drugs for the treatment of triple-negative breast cancer. By targeting casein kinase 2, the research identifies etravirine, an FDA-approved antiviral drug, as a potential candidate for repurposing as a TNBC treatment, paving the way for further research and potentially improving outcomes for patients battling this aggressive form of cancer.

Date :
  1. Date Completed 2023-10-11
  2. Date Revised 2023-10-11
Further Info :

Pubmed ID

37578958

DOI: Digital Object Identifier

PMC10424868

Related Literature

Article Analysis
・Effects of etravirine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.